L

Larimar Therapeutics
D

LRMR

3.92500
USD
-0.14
(-3.33%)
مغلق
حجم التداول
34,310
الربح لكل سهم
-2
العائد الربحي
-
P/E
-2
حجم السوق
335,942,289
الأخبار المقالات

العنوان: Larimar Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.